Aspects of the biochemical basis of depression

Destroy Depression

Depression Holistic Treatments

Get Instant Access

Research into the chemical pathology of depression has mainly concentrated on four major areas:

1. Changes in biogenic amine neurotransmitters in post-mortem brains from suicide victims.

2. Changes in cerebrospinal fluid (CSF) concentrations of amine metabolites from patients with depression.

3. Endocrine disturbances which appear to be coincidentally related to the onset of the illness.

4. Changes in neurotransmitter receptor function and density on platelets and lymphocytes from patients before and following effective treatment.

Approximately 30 years ago, Schildkraut postulated that noradrenaline may play a pivotal role in the aetiology of depression. Evidence in favour of this hypothesis was provided by the observation that the antihypertensive drug reserpine, which depletes both the central and peripheral vesicular stores of catecholamines such as noradrenaline, is likely to precipitate depression in patients in remission. The experimental drug alpha-methyl-paratyrosine that blocks the synthesis of noradrenaline by inhibiting the rate-limiting enzyme tyrosine hydroxylase was also shown to precipitate depression in patients during remission. While such findings are only indirect indicators that noradrenaline plays an important role in human behaviour, and may be defective in depression, more direct evidence is needed to substantiate the hypothesis. The most obvious approach would be to determine the concentration of noradrenaline and/or its major central metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in the brains of suicide victims. The problem with such post-mortem studies is that (a) the precise diagnosis may be uncertain, (b) there is usually a considerable postmortem delay before the brain is removed at autopsy and (c) suicide is often committed by taking an overdose of alcohol together with drugs which grossly affect central monoamine neurotransmitter function. Unless these variables are carefully controlled, the value of the results obtained from such analyses is uncertain. Nevertheless, there is evidence that the neurotransmitter receptors in post-mortem brain are less labile than the neurotransmitters that act upon them. The finding that the density of beta adrenoceptors is increased in cortical regions of the brains from suicide victims who had suffered from depression is evidence of disturbed noradrenergic function which is associated with some of the symptoms of the illness. Such observations are further supported by the increase in the density of beta adrenoceptors on the lymphocytes of untreated depressed patients. As the density of these receptors is normalized by effective antidepressant treatment, it has been postulated that changes in the beta receptor density may be a state marker of the condition (Table 7.1).

Other studies have shown that the elevation of growth hormone in the plasma following the administration of the alpha-2 adrenoceptor agonist clonidine is diminished in depressed patients, which suggests that central postsynaptic alpha-2 adrenoceptors are also subfunctional in such patients. This is perhaps the most consistent finding to have emerged in studies of the hypothalamic-pituitary axis in depression. As the clonidine response does not return to normal after effective antidepressant treatment, this is possibly a trait marker of depression. It should be emphasized that the reduced growth hormone response to clonidine cannot be accounted for by drug treatment, age or gender of the patient, which supports the view that the noradrenergic system is dysregulated in depression. Lastly, determination of the urine or plasma concentrations of MHPG (an indicator of central noradrenergic activity) suggests that central noradrenergic function is suboptimal in depression. Taken together, these results suggest that central noradrenergic function is decreased in depression, an event leading to the increase in the density of the postsynaptic beta adrenoceptors that show

Table 7.1. Changes in brain and tissue amine neurotransmitters in depressed patients which may be indicative of the mechanism of action of antidepressants

Evidence from the brains of depressed patients who committed suicide

• Increased density of beta adrenoceptors in cortical regions

• Increased density of 5-HT2A receptors in limbic regions

• Decreased concentration of 5-HIAA in several brain regions

• Increased muscarinic receptor density in limbic regions adaptive changes in response to the diminished synaptic concentration of the transmitter. It should be emphasized however that none of the studies of noradrenergic function in post-mortem material or tissues from depressed patients are entirely satisfactory. Many of the findings cannot be replicated, the number of patients studied is relatively small and the tritiated ligands used to determine the receptor density for example vary in their selectivity.

There is also evidence that the density of muscarinic receptors is increased in limbic regions of depressed patients who have committed suicide. If it is assumed that such a change reflects an increased activity of the cholinergic system, it could help to explain the reduced noradrenergic function as there is both clinical and experimental evidence to suggest that increased central cholinergic activity can precipitate depression and reduce noradrenergic activity.

The role of serotonin (5-hydroxytryptamine, 5-HT) has also been extensively studied in depressed patients. Whereas the overall psycho-physiological effects of noradrenaline in the CNS appear to be linked to drive and motivation, 5-HT is primarily involved in the expression of mood. It is not surprising therefore to find that the serotonergic system is abnormal in depression. This is indicated by a reduction in the main 5-HT metabolite, 5-hydroxyindole acetic acid (5-HIAA), in the cerebrospinal fluid of severely depressed patients and a reduction in 5-HT and 5-HIAA in the limbic regions of the brain of suicide victims. The 5-HT receptor function also appears to be abnormal in depression. This is indicated by an increase in the density of cortical 5-HT2A receptors in the brains of suicide victims and also on the platelet membrane of depressed patients. Platelets may be considered as accessible models of the nerve terminal.

Thus platelets are, like neurons, of ectodermal origin and contain enzymes such as enolase that are otherwise restricted to neurons. In addition, platelets contain storage vesicles for 5-HT from which the amine is released by a calcium-dependent mechanism. An energy-dependent transport site for 5-HT also occurs on the platelet membrane, the structure of which is identical to that found on neurons in the brain. Furthermore, the platelet membrane contains 5-HT2A and alpha-2 adrenergic receptors that are functionally involved in platelet aggregation; there is evidence that the densities of these receptors are increased in depressed patients and largely normalized following effective treatment. Thus a number of important biochemical parameters may be determined from a platelet-rich plasma sample. It has been found, for example, that the transport of 3H-5-HT into the platelet is significantly reduced in the untreated depressed patient but largely returns to normal following effective treatment. This change occurs irrespective of the nature of the antidepressant used to treat the patient and may therefore be considered as a state marker of the illness.

The function of the 5-HT2A receptor also appears to be subnormal in the untreated patient as shown by diminished aggregatory response to the addition of 5-HT in vitro, but normalizes when the patient recovers. As the number of 5-HT2A receptors on the platelet membrane of depressed patients is increased (as shown by the increased binding of a specific ligand such as 3H-ketanserin) this finding suggests that the G protein transducer mechanism, which links the receptor to the second messenger phosphatidyl inositol system within the platelet, is possibly defective in depression. There is also evidence that the modulatory site on the 5-HT transporter, the imipramine binding site, is decreased in depression, but unlike the changes in 5-HT uptake, remains unchanged by effective treatment. This suggests that the number of imipramine binding sites on the platelet membrane is a trait marker of the condition. However, the precise relevance of this finding is uncertain as the binding of the more specific ligand, 3H-paroxetine, is unchanged in depression. These studies of platelet function before, during and following treatment can give important information of the biochemical processes which may be causally related to depression. However, it is still uncertain how the changes in platelet function precisely reflect those occurring in the brain. Platelets are unconnected with the nervous system and therefore the changes observed could be a reflection of the hormonal changes (for example, glucocorticoids) that occur in depression. There is also evidence that some of the alterations in platelet function are a consequence of low molecular weight plasma factors that occur in the depressed patient and which are absent following effective antidepressant treatment (Table 7.2).

More recently, several studies in both the United States and the UK have shown that patients undergoing treatment with an SSRI will rapidly relapse when given an amino acid-containing drink that is deficient in tryptophan. The onset of the symptoms of depression is rapid (less than 24 hours); there is clinical and experimental evidence that the reduction in brain serotonin

Table 7.2. Other clinical studies implicating an abnormal biogenic amine function in depression

• Decreased 5-HIAA concentration in CSF

• Decreased HVA (main dopamine metabolite) in CSF

• Decreased urinary excretion of the main central noradrenaline metabolite MHPG (?)

• Rapid relapse following administration of a tryptophan-free amino acid drink to depressed patients being treated with an SSRI

• Rapid relapse following administration of the tyrosine hydroxylase inhibitor alpha-methyl-tyrosine to depressed patients who respond to a noradrenaline reuptake inhibitor such as desipramine

? These findings are equivocal.

as a consequence of the lack of tryptophan is the cause of the altered mood state. However, those depressed patients who responded to desipramine, which enhances noradrenergic function, did not relapse when given the tryptophan-free drink. Such studies provide further evidence to suggest that serotonin plays a crucial role in the aetiology of depression. They also raise the possibility that some depressed patients have a pronounced deficit in noradrenergic function rather than serotonergic function, which may account for the differential response of some depressed patients to antidepressants which augment the serotonergic or noradrenergic system (Table 7.3).

While there has been considerable attention devoted to changes in noradrenergic and serotonergic function in depression, less attention has been paid to the possible involvement of dopamine in this disorder. This is surprising as anhedonia is a characteristic feature of major depression and a defect in dopaminergic function is thought to be causally involved in this symptom. Several studies have shown that the concentration of the main dopamine metabolite, homovanillic acid (HVA), is decreased in the CSF of depressed patients, particularly those with psychomotor retardation. These depressed patients who attempted suicide were also found to have a decreased urinary excretion of HVA and the second major dopamine metabolite, dihydroxyphenylacetic acid (DOPAC). It is of course possible that the dopamine deficit is more a reflection of the degree of retardation rather than the psychological state as similar changes in CSF HVA concentrations have been reported to occur in patients with Parkinson's disease. This implies that the changes in the basal ganglia probably overshadow any changes in the mesolimbic dopaminergic system as the contribution of this area is relatively minor.

With regard to the specific action of antidepressants on the dopaminergic system, there is evidence that buproprion (not marketed in most countries in Western Europe as an antidepressant but available in North America), amineptine and nomifensin (withdrawn because of the rare occurrence of haemolysis) owed their antidepressant efficacy to their ability to increase central dopaminergic function. There are also open label studies to suggest

Table 7.3. Evidence from depressed patients

• Increased density of 5-HT2a receptors on the platelet membrane

• Decreased uptake of 3H-5-HT into platelet

• Increased beta adrenoceptor density on lymphocyte membrane

• Increased density of alpha-2 adrenoceptors on platelet membranes (*)

• Blunted growth hormone response to a clonidine challenge

• Blunted prolactin response to a fenfluramine challenge

* These findings are equivocal.

that the novel dopamine receptor agonist roxindole and the selective dopamine uptake inhibitor pramipexole may have antidepressant action.

Thus when the results of the studies on platelets, lymphocytes, changes in cerebrospinal fluid metabolites of brain monoamines and the post-mortem studies are taken into account it may be concluded that a major abnormality in both noradrenergic and serotonergic function occurs in depression, and that such changes could be causally related to the disease process.

Circadian changes in neurotransmitter function in depression

Both clinical and experimental studies have shown that a number of transmitter receptors and amine transport processes show circadian changes. It is well established that depression is associated with a disruption of the circadian rhythm as shown by changes in a number of behavioural, autonomic and neuroendocrine aspects. One of the main consequences of effective treatment is a return of the circadian rhythm to normality. For example, it has been shown that the 5-HT uptake into the platelets of depressed patients is largely unchanged between 0600 and 1200 hours, whereas the 5-HT transport in control subjects shows a significant decrease over this period. The normal rhythm in 5-HT transport is only reestablished when the depressed patient responds to treatment. Thus it may be hypothesized that the mode of action of antidepressants is to normalize disrupted circadian rhythms. Only when the circadian rhythm has returned to normal can full clinical recovery be established.

Chronobiological studies have shown that circadian rhythms occur in the responsivity of animals to light, dark and psychotropic drugs. This implies that the timing of drug administration so that the drug reaches the target organ at its optimum sensitivity could help to improve its therapeutic efficiency. The results of experimental studies suggest that most antidepressants delay the circadian phase and lengthen the circadian period. These changes could be due to the drugs acting on the circadian pacemaker in the superchiasmatic nucleus. However, other brain regions could also be responsible together with antidepressant-induced changes in the retina which would lead to a modification of the processing of light stimuli; the lateral geniculate nucleus may also have a role to play. Seasonal affective disorder (SAD) generally consists of recurrent depressive episodes in autumn and winter that alternate with euthmia or hypomania in spring and summer. The seasonal rhythms of mood, sleep and weight change seen in SAD patients resemble hibernation seen in animals. This led to the hypothesis that extension of the photoperiod in winter could counteract the depressive symptoms. Exposure to bright light had indeed been shown to be efficacious. Clinical studies show that carbohydrate craving, a common feature of

SAD, is possibly linked to a decreased serotonin turnover. Such a hypothesis is supported by the fact that the serotonin releasing agent D-fenfluramine is effective in treating SAD. Chronobiology is clearly an important area of research for the psychopharmacologist which needs more attention.

Was this article helpful?

0 0
Beat Depression Now

Beat Depression Now

Let me be up front. My intention is to sell you something. Normally, it's not wise to come out and say that. However, I can do so because I have such an incredible deal for you that you'd be crazy to pass on it.

Get My Free Ebook


Responses

  • DOMINIK
    What is electonmembranehypothesis on biochemical basis of depression?
    2 years ago

Post a comment